IDHC vs. DXRX, AGL, YGEN, ABDX, PRM, GDR, GENI, VRCI, DMTR, and LLAI
Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Verici Dx (VRCI), Deepmatter Group (DMTR), and LungLife AI (LLAI). These companies are all part of the "diagnostics & research" industry.
Integrated Diagnostics vs. Its Competitors
Integrated Diagnostics (LON:IDHC) and Diaceutics (LON:DXRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.
In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.
Integrated Diagnostics has higher revenue and earnings than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.
Integrated Diagnostics has a net margin of 17.21% compared to Diaceutics' net margin of -10.90%. Integrated Diagnostics' return on equity of 30.45% beat Diaceutics' return on equity.
Integrated Diagnostics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
43.0% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 52.4% of Diaceutics shares are held by institutional investors. 34.0% of Integrated Diagnostics shares are held by company insiders. Comparatively, 34.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Diaceutics has a consensus price target of GBX 160, suggesting a potential upside of 33.33%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Integrated Diagnostics.
Summary
Integrated Diagnostics beats Diaceutics on 8 of the 14 factors compared between the two stocks.
Get Integrated Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IDHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integrated Diagnostics Competitors List
Related Companies and Tools
This page (LON:IDHC) was last updated on 7/8/2025 by MarketBeat.com Staff
Free IDHC Stock Alerts